- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07919470
Busulfan-Based Versus TBI-Based Conditioning for Adult ALL-CR2 Allo-HSCT
Busulfan Based Versus Total Body Irradiation Based for Adults Acute B Lymphoblastic Leukemia in CR2: An Multicenter, Non-Inferiority Study
This is an multicenter, non-inferiority randomized controlled trial. Adult patients (14-65 years) with acute lymphoblastic leukemia in second complete remission (CR2) scheduled for allogeneic hematopoietic stem-cell transplantation (allo-HSCT) will be randomized 1:1 to receive either busulfan-based chemotherapy-only conditioning (experimental arm) or total-body-irradiation (TBI)-based conditioning (active comparator arm). The primary objective is to test the non-inferiority of chemotherapy-based conditioning versus TBI-based conditioning regarding 1-year leukemia-free survival (LFS). Secondary endpoints include treatment-related mortality (TRM), cumulative incidence of relapse (CIR), graft-versus-host-disease (GVHD), and overall survival (OS). All patients receive uniform GVHD prophylaxis and post-transplant supportive care.
Přehled studie
Postavení
Intervence / Léčba
Detailní popis
Adult ALL patients achieving second complete remission (CR2) represent a high-risk population for relapse after allo-HSCT. Allo-HSCT is the standard curative therapy, yet optimal preparative conditioning remains controversial. Most published evidence focuses on CR1 ALL patients; prospective head-to-head comparison between chemotherapy-only and TBI-based conditioning specifically for adult CR2 ALL is scarce and mainly relies on retrospective cohorts. While TBI-based conditioning provides favorable anti-leukemia effect, it carries substantial acute and late toxicities. Chemotherapy-only conditioning may reduce radiation-related toxicities but raises concern for higher relapse risk. This multicenter randomized phase III non-inferiority trial aims to provide prospective evidence to guide conditioning-regimen selection for adult ALL-CR2 patients undergoing allo-HSCT.
Eligible subjects are randomly assigned 1:1 via central stratified block randomization (variable block sizes:4,6,8). Investigators and participants are not blinded to treatment assignment; outcome assessment and statistical analysis are performed in a blinded fashion.
Experimental Arm (Busulfan-based chemotherapy-only conditioning): Busulfan 0.8 mg/kg q.i.d. day -8 to -6; cyclophosphamide 1.8 g/m²/day day -5, -4; semustine 250 mg/m² day -3. For haploidentical transplant recipients: rabbit-ATG 2.5 mg/kg/day day -5 to -2.
Active Comparator Arm (TBI-based conditioning): Total-body irradiation 770 cGy on day -6; cyclophosphamide 1.8 g/m²/day day -5, -4; semustine 250 mg/m² day -3. For haploidentical transplant recipients: rabbit-ATG 2.5 mg/kg/day day -5 to -2.
Grafts consist of G-CSF-mobilized bone marrow plus peripheral-blood stem cells. Uniform post-transplant GVHD prophylaxis includes cyclosporine-A, mycophenolate mofetil, and short-course methotrexate.
Planned follow-up time-points: +1, +2, +3, +4.5, +6, +9, +12, +18, +24, +36, +48, +60 months post-transplant. Assessments include bone-marrow morphology, multiparameter flow MRD, molecular MRD (fusion gene / Ig-TCR / NGS), chimerism analysis, complete blood count, biochemistry, virology screening, and GVHD evaluation per NIH consensus criteria.
Typ studie
Zápis (Odhadovaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
- Jméno: Yu Wang
- Telefonní číslo: 8610-8832-6005
- E-mail: ywyw3172@sina.com
Studijní místa
-
-
-
Beijing, Čína
- Peking University People's Hospital, Beijing Lu Daopei Hematology Hospital, Hebei Yanda Lu Daopei Hospital, Nanfang Hospital, Southern Medical University
-
Kontakt:
- Xiaojun Huang
- Telefonní číslo: 8610-8832-6005
- E-mail: huangxiaojun@bjmu.edu.cn
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Age ≥ 14 and ≤ 65 years (inclusive).
- Diagnosis of acute lymphoblastic leukemia according to NCCN diagnostic criteria.
- Confirmed second complete remission (CR2) before allogeneic hematopoietic stem-cell transplantation.
- Planned to undergo allo-HSCT.
- ECOG performance status < 3.
- Written informed consent obtained.
Exclusion Criteria:
-
Diagnosis of acute biphenotypic leukemia.
-
Uncontrolled active infection at screening.
-
Significant organ dysfunction:
- Liver: ALT/AST > 3.0 × ULN and/or total bilirubin > 1.5 × ULN; severe cirrhosis, portal hypertension or active liver disease.
- Renal: eGFR < 60 mL/min/1.73 m² by CKD-EPI formula or serum creatinine > 1.5 × ULN; regular dialysis requirement.
- Cardiac: NYHA class III-IV heart failure; unstable angina / myocardial infarction / coronary revascularization within prior 6 months; LVEF < 50 %; clinically significant uncontrolled arrhythmia.
- Pulmonary: chronic lung disease requiring long-term oxygen therapy; resting SpO₂ < 92 % (room-air).
-
Participation in another investigational drug trial within past 3 months.
-
Psychiatric disorders interfering with protocol compliance.
-
History of other malignant neoplasms within 2 years prior to screening.
-
Any condition judged by investigator rendering subject unsuitable for trial participation.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Chemotherapy-only Conditioning Regimen
intervention: Drug: Busulfan: 0.8 mg/kg intravenous, four times daily, day -8 to day -6 Drug: Cyclophosphamide: 1.8 g/m²/day intravenous, day -5, day -4 Drug: Semustine: 250 mg/m² oral, day -3 Drug: Rabbit anti-thymocyte globulin (ATG): 2.5 mg/kg/day intravenous day -5 to -2 (only for haploidentical transplant recipients) All subjects receive identical post-transplant GVHD-prophylaxis: cyclosporine-A, mycophenolate mofetil, short-course methotrexate; standard supportive care. |
Experimental Arm (Chemotherapy-based conditioning): Busulfan 0.8 mg/kg q.i.d. day -8 to -6; cyclophosphamide 1.8 g/m²/day day -5, -4; semustine 250 mg/m² day -3. For haploidentical transplant recipients: rabbit-ATG 2.5 mg/kg/day day -5 to -2. |
|
Aktivní komparátor: TBI-based Conditioning Regimen
intervention Radiation: Total-Body Irradiation (TBI): 770 cGy administered on day -6 Drug: Cyclophosphamide: 1.8 g/m²/day intravenous, day -5, day -4 Drug: Semustine: 250 mg/m² oral, day -3 Drug: Rabbit anti-thymocyte globulin (ATG): 2.5 mg/kg/day intravenous day -5 to -2 (only for haploidentical transplant recipients) All subjects receive identical post-transplant GVHD-prophylaxis: cyclosporine-A, mycophenolate mofetil, short-course methotrexate; standard supportive care. |
Active Comparator Arm (TBI-based conditioning): Total-body irradiation 770 cGy on day -6; cyclophosphamide 1.8 g/m²/day day -5, -4; semustine 250 mg/m² day -3. For haploidentical transplant recipients: rabbit-ATG 2.5 mg/kg/day day -5 to -2. |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
1-Year Leukemia-Free Survival (LFS)
Časové okno: 12 months post-hematopoietic stem-cell infusion]
|
Time from stem-cell infusion to leukemia relapse or death from any cause, whichever occurs first. |
12 months post-hematopoietic stem-cell infusion]
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
1-Year Treatment-Related Mortality (TRM)
Časové okno: 12 months post-transplantation
|
Cumulative incidence of non-relapse-related death after transplantation (competing risk: leukemia relapse). |
12 months post-transplantation
|
|
Cumulative Incidence of Relapse (CIR)
Časové okno: 1-year, 2-year, 3-year post-transplantation
|
Cumulative probability of hematologic or molecular leukemia relapse with death as competing risk event. |
1-year, 2-year, 3-year post-transplantation
|
|
Cumulative Incidence of Acute and Chronic Graft-Versus-Host Disease (GVHD)
Časové okno: Day 100, 1-year, 3-year post-transplantation
|
Cumulative incidence of grade II-IV, grade III-IV acute GVHD (100-day landmark); cumulative incidence of mild/moderate/severe chronic GVHD within 3 years, graded according to NIH GVHD consensus criteria. |
Day 100, 1-year, 3-year post-transplantation
|
|
Overall Survival (OS)
Časové okno: 1-year, 2-year, 3-year post-transplantation
|
Time from stem-cell infusion until death from any cause. |
1-year, 2-year, 3-year post-transplantation
|
|
Conditioning-related organ toxicities
Časové okno: Conditioning start up to post-transplant day +30
|
Incidence of grade 1-4 cardiac, hepatic, renal, gastrointestinal and mucosal toxicities from conditioning initiation up to day +30 post-transplantation, graded by WHO organ-toxicity scale. |
Conditioning start up to post-transplant day +30
|
|
Hematopoietic engraftment
Časové okno: Day 30 and Day 90 post-transplantation
|
Neutrophil engraftment: sustained ANC ≥ 0.5 × 10⁹/L for three consecutive days; platelet engraftment: sustained PLT ≥ 20 × 10⁹/L without transfusion support for seven consecutive days. |
Day 30 and Day 90 post-transplantation
|
|
Molecular/Flow-MRD status post-transplant
Časové okno: +1, +2, +3, +6, +12 months post-transplantation
|
MRD positive defined as flow cytometry ≥ 0.01 %; or detectable quantifiable fusion-gene / Ig-TCR / NGS clonal signal above assay sensitivity threshold at serial follow-up time-points. |
+1, +2, +3, +6, +12 months post-transplantation
|
Spolupracovníci a vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Xiao-Jun Huang, Peking University Institute of Hematology
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- ALL-CR2-TBI-Bu
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .